Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,806 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.
Miyakawa Y, Katsutani S, Yano T, Nomura S, Nishiwaki K, Tomiyama Y, Higashihara M, Shirasugi Y, Nishikawa M, Ozaki K, Abe T, Kikuchi K, Kanakura Y, Fujimura K, Ikeda Y, Okamoto S. Miyakawa Y, et al. Among authors: nomura s. Int J Hematol. 2015 Dec;102(6):654-61. doi: 10.1007/s12185-015-1887-9. Int J Hematol. 2015. PMID: 26466831 Clinical Trial.
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan.
Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, Teramura M, Koda K, Nomura S, Sugihara S, Shimomura T, Fujimoto TT, Oyashiki K, Ikeda Y. Fujimura K, et al. Among authors: nomura s. Int J Hematol. 2005 Feb;81(2):162-8. doi: 10.1532/ijh97.04146. Int J Hematol. 2005. PMID: 15765787
A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. Tomiyama Y, et al. Among authors: nomura s. J Thromb Haemost. 2012 May;10(5):799-806. doi: 10.1111/j.1538-7836.2012.04695.x. J Thromb Haemost. 2012. PMID: 22409309 Free article. Clinical Trial.
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y; KMF investigators. Kobayashi T, et al. Among authors: nomura s. Int J Hematol. 2015 Jan;101(1):37-45. doi: 10.1007/s12185-014-1696-6. Epub 2014 Nov 11. Int J Hematol. 2015. PMID: 25385278
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators. Matsumura-Kimoto Y, et al. Among authors: nomura s. Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29. Int J Hematol. 2018. PMID: 29380179
2,806 results